Duchenne Muscular Dystrophy Treatment Market - Growth Drivers and Challenges
Growth Drivers
- Amplification of financial backing: Medicare spending on duchenne muscular dystrophy (DMD) therapies was estimated at USD 104 million from 2017 to 2022 based on CMS Medicaid State Drug Utilization data, with Medicaid spending significantly higher at USD 1.1 billion during the same period. The total combined spending on key DMD medications (eteplirsen, golodirsen, casimersen) increased from USD 25 million in 2017 to approximately USD 327 million in 2022, based on NLM report in March 2024. This highlights the growing recognition of DMD in creating new business opportunities via a reduction in patient financial burdens.
- Increased investments and participation in R&D: Continuous effort towards extensive research, development, and deployment is propelling expansion in the Duchenne muscular dystrophy treatment market. As evidence, the Parent Project Muscular Therapy report in November 2023 states that it has funded over USD 7 million in a variety of gene therapies. Further, CDC’s Muscular Dystrophy Program funding is set to rise from USD 7.5 million to USD 10 million. Moreover, these investments are accelerating therapeutic innovation in this sector.
- Rising patient pool and disease prevalence: The Parent Project Muscular Therapy report in 2025 estimates that 20,000 babies worldwide are born with the disease and nearly 15,000 men are living with Duchenne today in the U.S. These figures indicate a rising patient base due to improved diagnostics and longer survival rates, directly increasing therapeutic demand. Growing prevalence especially in developed regions drives procurement and clinical trial activity.
Percentage of Male Population with Duchenne Muscular Dystrophy Varied by Age
|
Age |
Percentage |
|
5-9 |
29% |
|
10-14 |
82% |
|
15-24 |
90% |
Source: CDC, January 2025
Challenges
- Regulatory compliance-related hurdles: Strict requirements from indifferent regulations in various landscapes pose a significant hurdle for the Duchenne muscular dystrophy treatment market. The elongated process of therapy approvals often delays product launch and restricts optimum profitability. For instance, in 2022, the Pharmaceuticals and Medical Devices Agency (PMDA) postponed clearance for exon-skipping therapies. To resolve this issue, Sarepta expedited review pathways, where the fast-tracked FDA allowances reduced review times in 2023.
Duchenne Muscular Dystrophy Treatment Market Size and Forecast:
|
Base Year |
2025 |
|
Forecast Year |
2026-2035 |
|
CAGR |
12.8% |
|
Base Year Market Size (2025) |
USD 1.9 million |
|
Forecast Year Market Size (2035) |
USD 6.2 million |
|
Regional Scope |
|
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of the duchenne muscular dystrophy treatment market was over USD 1.9 million.
The market size for the duchenne muscular dystrophy treatment market size was over USD 1.9 million in 2025 and is estimated to reach USD 6.2 million by the end of 2035, expanding at a CAGR of 12.8% during the forecast timeline, i.e., 2026-2035.
The major players in the market are Sarepta Therapeutics, Pfizer, Roche, Solid Biosciences, Santhera Pharmaceuticals, Wave Life Sciences, Italfarmaco, and others.
In terms of distribution channel, hospital pharmacies dominate the segment and are expected to have the revenue share of 65.5%.
The market in North America is anticipated to attain the largest share of 42.2% in the duchenne muscular dystrophy treatment market throughout the analyzed timeframe.
